Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company ...

Breathing—a natural and essential process—can be an incredibly labored process for people with cystic fibrosis. CF, a genetic ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) presented promising clinical data on their CFTR modulator ALYFTREK at the European Cystic Fibrosis Conference, showcasing improved outcomes for patients with ...

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has announced data across multiple studies demonstrating positive clinical ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive ...

Sionna Therapeutics shares rose after reporting positive preliminary data from its cystic fibrosis drug trial. Shares traded 5.9% higher at $16.92.

Preclinical data suggest these compounds, when used in combination, have the potential to dramatically improve clinical outcomes and quality of life for people with CF.” Sionna has completed Phase 1 ...

The 30th annual Battle Against Cystic Fibrosis football game will be held this Friday to raise money for Cystic Fibrosis ...

Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment ...

will be presented at the European Cystic Fibrosis Society’s conference in Milan from June 4-7, 2025. The presentation will explore how these NBD1 stabilizers can synergize with CFTR modulators ...

48th European Cystic Fibrosis Conference, being held June 4-7, 2025 in Milan, Italy. Details of the oral presentation are as follows: Abstract Title: Stabilizers of CFTR NBD1 synergize with ...

48 th European Cystic Fibrosis Conference, being held June 4-7, 2025 in Milan, Italy. Details of the oral presentation are as follows: Abstract Title: Stabilizers of CFTR NBD1 synergize with ...